Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q0HZ
|
|||
| Former ID |
DIB001576
|
|||
| Drug Name |
Elpamotide
|
|||
| Synonyms |
OTS-102; VEGFR2-169; Epitope peptide vaccine (pancreatic cancer), Wakayama University; VEGFR2-epitope peptide, Wakayama
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Biliary cancer [ICD-11: 2E92.7; ICD-10: D13.4] | Phase 1/2 | [1] | |
| Company |
OncoTherapy Science Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00655785) Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2). U.S. National Institutes of Health. | |||
| REF 2 | Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. Cancer Sci. 2012 Dec;103(12):2135-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.